HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation.

Abstract
Tuftsin (TF) is an immunomodulator tetrapeptide (Thr-Lys-Pro-Arg) that binds to the receptor neuropilin-1 (Nrp1) on the surface of cells. Many reports have described anti-tumor activity of tuftsin to relate with nonspecific activation of the host immune system. Lidamycin (LDM) that displays extremely potent cytotoxicity to cancer cells is composed of an apoprotein (LDP) and an enediyne chromophore (AE). In addition, Ec is an EGFR-targeting oligopeptide. In the present study, LDP was used as protein scaffold and the specific carrier for the highly potent AE. Genetically engineered fusion proteins LDP-TF and Ec-LDP-TF were prepared; then, the enediyne-energized fusion protein Ec-LDM-TF was generated by integration of AE into Ec-LDP-TF. The tuftsin-based fusion proteins LDP-TF and Ec-LDP-TF significantly enhanced the phagocytotic activity of macrophages as compared with LDP (P < 0.05). Ec-LDP-TF effectively bound to tumor cells and macrophages; furthermore, it markedly suppressed the growth of human epidermoid carcinoma A431 xenograft in athymic mice by 84.2 % (P < 0.05) with up-regulated expression of TNF-α and IFN-γ. Ec-LDM-TF further augmented the therapeutic efficacy, inhibiting the growth of A431 xenograft by 90.9 % (P < 0.05); notably, the Ec-LDM-TF caused marked down-regulation of CD47 in A431 cells. Moreover, the best therapeutic effect was recorded in the group of animals treated with the combination of Ec-LDP-TF with Ec-LDM-TF. The results suggest that tuftsin-based, enediyne-energized, and EGFR-targeting fusion proteins exert highly antitumor efficacy with CD47 modulation. Tuftsin-based fusion proteins are potentially useful for treatment of EGFR- and CD47-overexpressing cancers.
AuthorsWen-Juan Liu, Xiu-Jun Liu, Liang Li, Yi Li, Sheng-Hua Zhang, Yong-Su Zhen
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 63 Issue 12 Pg. 1261-72 (Dec 2014) ISSN: 1432-0851 [Electronic] Germany
PMID25164878 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CD47 Antigen
  • Enediynes
  • Immunotoxins
  • Recombinant Fusion Proteins
  • ErbB Receptors
  • Tuftsin
Topics
  • Animals
  • CD47 Antigen (immunology)
  • Carcinoma, Squamous Cell (immunology, therapy)
  • Cell Communication
  • Cell Line, Tumor
  • Down-Regulation
  • Enediynes (chemistry, pharmacology)
  • ErbB Receptors (immunology)
  • Female
  • Humans
  • Immunotoxins (chemistry, immunology, pharmacology)
  • Mice
  • Mice, Inbred BALB C
  • Murine pneumonia virus
  • Recombinant Fusion Proteins (chemistry, immunology, pharmacology)
  • Tuftsin (chemistry, immunology, pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: